Have any questions? 706-721-6582 or cts@augusta.edu
- Amifampridine for the Treatment of Transient Vocal Weakness after OnabotulinumtoxinA Injection for Spasmodic Dysphonia
Clinical Trial
Amifampridine for the Treatment of Transient Vocal Weakness after OnabotulinumtoxinA Injection for Spasmodic Dysphonia
In this study, we will be looking at how well the drug amifampridine, also known as Firdapse, works to relieve the temporary symptoms of voice weakness and breathiness that can occur after a patient with adductor spasmodic dysphonia receive a Botox injection to treat their condition. Participation in the full study will last about 2 months.
Eligibility Criteria
- Inclusion Criteria: You are 18 years old or older You receive onabotulinumtoxinA treatment for Adductor Spasmodic Dysphonia Your voice gets breathy or weak within 5 days following your onabotulinumtoxinA injection Exclusion Criteria: Known history of seizures Known allergy to the drug or its components.
RESEARCH. INNOVATION. DISCOVERY.